Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

July 04, 2015 10:17 AM ET


Company Overview of ContraVir Pharmaceuticals, Inc.

Company Overview

ContraVir Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the discovery and development of targeted antiviral therapies. Its lead candidate, FV-100, is an orally available nucleoside analogue prodrug that is being developed for the treatment of herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus. The company has completed Phase I trials of FV-100 in volunteers, as well as a Phase IIa clinical trial in shingles patients. It also plans to conduct a trial in patients with shingles to further explore FV-100's potential to treat the long-lasting nerve pain typically associated with shingles. The company was founded in 201...

399 Thornall Street

First Floor

Edison, NJ 08837

United States

Founded in 2013

3 Employees





Key Executives for ContraVir Pharmaceuticals, Inc.

Chief Executive Officer and Director
Age: 53
Total Annual Compensation: $86.2K
Chief Financial Officer
Age: 46
Total Annual Compensation: $4.9K
Compensation as of Fiscal Year 2014.

ContraVir Pharmaceuticals, Inc. Key Developments

ContraVir Pharmaceuticals, Inc. Presents at BIO International Convention 2015, Jun-17-2015 04:00 PM

ContraVir Pharmaceuticals, Inc. Presents at BIO International Convention 2015, Jun-17-2015 04:00 PM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States. Speakers: James E. Sapirstein, Chief Executive Officer and Director.

ContraVir Pharmaceuticals to Initiate Pivotal Phase 3 Study of FV-100 for Prevention of Shingles-Associated PHN

ContraVir Pharmaceuticals, Inc. announced the outcome of a recent End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding the company's lead drug candidate, FV-100, for the prevention of debilitating shingles-associated pain known as post-herpetic neuralgia (PHN). The FDA has agreed to, with minor modifications, ContraVir's proposed clinical protocol, which is designed as a pivotal Phase 3 study. While antivirals are approved to treat the viral infection underlying shingles, there are currently no approved antiviral therapies for preventing PHN. It remains a major unmet medical need, and ContraVir has been exploring the potential of FV-100 to prevent the severe and long-lasting effects of this condition. The Phase 3 study will build upon prior clinical results for FV-100, including Phase 1 trials as well as a large Phase 2 clinical trial in shingles patients, which demonstrated excellent safety and tolerability for FV-100.

ContraVir Pharmaceuticals Seeks Acquisitions

ContraVir Pharmaceuticals, Inc. (NasdaqCM:CTRV) intends to use the net proceeds to repay any debts and/or invest in or acquire complementary businesses, products or technologies, although they have no current commitments or agreements with respect to any such investments or acquisitions as of the date of this prospectus.

Similar Private Companies By Industry

Company Name Region
Eurand, Inc. United States
Nelco Laboratories, Inc. United States
ProlX Pharmaceuticals Corporation United States
Cedarburg Pharmaceuticals, Inc. United States
TAXIS Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

Private Placement
February 26, 2015
Private Placement
October 14, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ContraVir Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at